تحميل...

10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study

BACKGROUND. Vascular endothelial growth factor (VEGF)-targeted agents are standard therapies for metastatic renal cell carcinoma (mRCC), associated with variable tumor shrinkage. Response Evaluation Criteria in Solid Tumors (RECIST) is of limited utility in this setting, and other imaging changes ar...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Krajewski, Katherine M., Franchetti, Yoko, Nishino, Mizuki, Fay, André P., Ramaiya, Nikhil, Van den Abbeele, Annick D., Choueiri, Toni K.
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	AlphaMed Press 2014
الموضوعات:	Genitourinary Cancer: Renal, Bladder, and Testicular
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4012965/ https://ncbi.nlm.nih.gov/pubmed/24755461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0391
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study

مواد مشابهة